Fluciclovine F-18 Patent Expiration
Fluciclovine F-18 is Used for diagnostic imaging of suspected prostate cancer recurrence in adults based on elevated blood prostate specific antigen levels. It was first introduced by Blue Earth Diagnostics Ltd
Fluciclovine F-18 Patents
Given below is the list of patents protecting Fluciclovine F-18, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Axumin | US10010632 | Precursor compound of radioactive halogen-labeled organic compound | Nov 28, 2026 | Blue Earth |
| Axumin | US10124079 | Imaging of metastatic or recurrent cancer | Dec 30, 2035 | Blue Earth |
| Axumin | US10716868 | Imaging of metastatic or recurrent cancer | Dec 30, 2035 | Blue Earth |
| Axumin | US10933147 | Imaging of metastatic or recurrent cancer | Dec 30, 2035 | Blue Earth |
| Axumin | US10953112 | Precursor compound of radioactive halogen-labeled organic compound | Nov 28, 2026 | Blue Earth |
| Axumin | US10967077 | Imaging of metastatic or recurrent cancer | Dec 30, 2035 | Blue Earth |
| Axumin | US11980674 | Imaging of metastatic or recurrent cancer | Apr 23, 2042 | Blue Earth |
| Axumin | US5808146 | Amino acid analogs for tumor imaging |
Nov 09, 2020
(Expired) | Blue Earth |
| Axumin | US9387266 | Precursor compound of radioactive halogen-labeled organic compound | Nov 28, 2026 | Blue Earth |